Clinical Trial Update: Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma [Phase 2]

View source ↗

Summary

A Phase 2 trial of INQOVI (decitabine/cedazuridine) in patients with BAP1 tumor predisposition syndrome and subclinical, early-stage mesothelioma is currently s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bap1 Tumor Predisposition Syndrome
• Mesothelioma

Drugs mentioned

• INQOVI (decitabine/cedazuridine) (decitabine/cedazuridine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Mesothelioma, Malignant Mesothelioma (MM) | Phase 2 | Status: SUSPENDED